{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:20:30Z","timestamp":1793020830558,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ahj.2026.107359","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:21:28Z","timestamp":1769530888000},"page":"107359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk"],"prefix":"10.1016","volume":"296","author":[{"given":"Lee-Shing","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Chasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gabovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Colling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Crossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Gaziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Blood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ahj.2026.107359_bib0001","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5S","key":"10.1016\/j.ahj.2026.107359_bib0003","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney disease: improving global outcomes (KDIGO) diabetes work group","year":"2022","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.ahj.2026.107359_bib0004","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2026.107359_bib0005","unstructured":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD | European Heart Journal | Oxford Academic. accessed 4 June 2025. https:\/\/academic.oup.com\/eurheartj\/article\/41\/2\/255\/5556890."},{"issue":"9","key":"10.1016\/j.ahj.2026.107359_bib0006","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes","volume":"76","author":"Das","year":"2020","journal-title":"JACC"},{"issue":"18","key":"10.1016\/j.ahj.2026.107359_bib0007","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ahj.2026.107359_bib0008","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1161\/CIR.0000000000001040","article-title":"Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association","volume":"145","author":"Joseph","year":"2022","journal-title":"Circulation"},{"issue":"Supplement_1","key":"10.1016\/j.ahj.2026.107359_bib0009","first-page":"S158","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016835","article-title":"Gaps in evidence-based therapy use in insured patients in the united states with type 2 diabetes mellitus and atherosclerotic cardiovascular disease","volume":"10","author":"Nelson","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.48030","article-title":"Use of lipid-, blood pressure\u2013, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"5","author":"Nelson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ahj.2026.107359_bib0012","doi-asserted-by":"crossref","unstructured":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease | diabetes care | American Diabetes Association. accessed 4 June 2025. https:\/\/diabetesjournals-org.ezproxy.bu.edu\/care\/article\/45\/12\/2900\/147676\/Prescription-Patterns-of-Cardiovascular-and-Kidney.","DOI":"10.2337\/dc22-0614"},{"issue":"1","key":"10.1016\/j.ahj.2026.107359_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2022.3839","article-title":"Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice","volume":"8","author":"Nanna","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0014","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc21-1815","article-title":"Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: Insights from the department of veterans affairs","volume":"45","author":"Mahtta","year":"2022","journal-title":"Diabet Care"},{"issue":"1","key":"10.1016\/j.ahj.2026.107359_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jamacardio.2022.4018","article-title":"Results of a remotely delivered hypertension and lipid program in more than 10 000 patients across a diverse health care network","volume":"8","author":"Blood","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0016","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1055\/s-0041-1739195","article-title":"Workflow automation for a virtual hypertension management program","volume":"12","author":"Gordon","year":"2021","journal-title":"Appl Clin Inform"},{"issue":"1","key":"10.1016\/j.ahj.2026.107359_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13098-022-00785-1","article-title":"Adherence and persistence rates of major antidiabetic medications: a review","volume":"14","author":"Lee","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.ahj.2026.107359_bib0018","author":"Liss"},{"issue":"1","key":"10.1016\/j.ahj.2026.107359_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jamacardio.2022.4018","article-title":"Results of a remotely delivered hypertension and lipid program in more than 10 000 patients across a diverse health care network","volume":"8","author":"Blood","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1161\/CIRCULATIONAHA.120.051913","article-title":"Digital care transformation: interim report from the first 5,000 patients enrolled in a remote algorithm-based cardiovascular risk management program to improve lipid and hypertension control","volume":"143","author":"Scirica","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0021","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1161\/CIRCULATIONAHA.120.051913","article-title":"Digital care transformation","volume":"143","author":"Scirica","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ahj.2026.107359_bib0022","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1161\/HYPERTENSIONAHA.124.24475","article-title":"The long-term blood pressure trends following a remote hypertension intervention: a secondary analysis of the digital care transformation - remotely delivered hypertension management program","volume":"82","author":"Hassan","year":"2025","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0023","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/clc.23141","article-title":"Development of an entirely remote, non-physician led hypertension management program","volume":"42","author":"Fisher","year":"2019","journal-title":"Clin Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2026.107359_bib0024","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jamacardio.2020.3757","article-title":"Remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction","volume":"5","author":"Desai","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2026.107359_bib0025","doi-asserted-by":"crossref","DOI":"10.1089\/pop.2024.0132","article-title":"Identifying patients with heart failure eligible for guideline-directed medical therapy","author":"Subramaniam","year":"2024","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.ahj.2026.107359_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ahj.2021.08.017","article-title":"Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program","volume":"243","author":"Plutzky","year":"2022","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0027","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pcd.2024.01.005","article-title":"Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and\/or kidney risk","volume":"18","author":"Blood","year":"2024","journal-title":"Prim Care Diabet"},{"issue":"23","key":"10.1016\/j.ahj.2026.107359_bib0028","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/CIRCULATIONAHA.124.069494","article-title":"Randomized evaluation of a remote management program to improve guideline-directed medical therapy: the DRIVE trial","volume":"149","author":"Blood","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107359_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2024.09.005","article-title":"Enrollment strategies in the era of digital revolution: Experience from a remote health management program","author":"Hassan","year":"2024","journal-title":"Am Heart J."},{"key":"10.1016\/j.ahj.2026.107359_bib0031","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2023.05.002","article-title":"Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry","volume":"263","author":"Arnold","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2026.107359_bib0032","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ahj.2025.01.003","article-title":"Type 2 diabetes disease and management patterns across a large, diverse healthcare system: Issues and opportunities for guideline-directed therapies","volume":"282","author":"Blood","year":"2025","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.ahj.2026.107359_bib0033","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/dom.15032","article-title":"Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study","volume":"25","author":"Arnold","year":"2023","journal-title":"Diabet Obes Metab"},{"issue":"11","key":"10.1016\/j.ahj.2026.107359_bib0034","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabet Care"},{"issue":"3","key":"10.1016\/j.ahj.2026.107359_bib0035","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"M","year":"2013","journal-title":"Lancet Diabet Endocrinol"},{"issue":"2","key":"10.1016\/j.ahj.2026.107359_bib0036","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ahj.2026.107359_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.ahj.2026.107359_bib0041","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.ahj.2026.107359_bib0042","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabet Care"},{"issue":"8","key":"10.1016\/j.ahj.2026.107359_bib0043","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ahj.2026.107359_bib0044","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabet Care"},{"issue":"7","key":"10.1016\/j.ahj.2026.107359_bib0045","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0046","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","article-title":"A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)","volume":"18","author":"Dungan","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"9951","key":"10.1016\/j.ahj.2026.107359_bib0047","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0048","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabet Endocrinol"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0049","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabet Endocrinol"},{"issue":"5","key":"10.1016\/j.ahj.2026.107359_bib0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabet Endocrinol"},{"issue":"6","key":"10.1016\/j.ahj.2026.107359_bib0051","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ahj.2026.107359_bib0052","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabet Endocrinol"},{"issue":"4","key":"10.1016\/j.ahj.2026.107359_bib0053","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:09:25Z","timestamp":1779091765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"alternative-id":["S0002870326000219"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107359","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107359"}}